Authors: ALA Y MORIN D MOUILLAC B SABATIER N VARGAS R COTTE N DECHAUX M ANTIGNAC C ARTHUS MF LONERGAN M TURNER MS BALESTRE MN ALONSO G HIBERT M BARBERIS C HENDY GN BICHET DG JARD S

Citation: Y. Ala et al., FUNCTIONAL-STUDIES OF 12 MUTANT V-2 VASOPRESSIN RECEPTORS RELATED TO NEPHROGENIC DIABETES-INSIPIDUS - MOLECULAR-BASIS OF A MILD CLINICAL PHENOTYPE, Journal of the American Society of Nephrology, 9(10), 1998, pp. 1861-1872

Authors: MORIN D ALA Y VARGAS R SABATIER N ANTIGNAC C DECHAUX M LOIRAT C BROYER M DUMAS R BICHET D JARD S BARBERIS C

Citation: D. Morin et al., FUNCTIONAL-STUDY OF V2 RECEPTOR GENE-MUTA TIONS RESPONSIBLE FOR CONGENITAL NEPHROGENIC DIABETES-INSIPIDUS, Archives de pediatrie, 4, 1997, pp. 193-194

Authors: ALA Y MORIN D MAHE E COTTE N MOUILLAC B JARD S BARBERIS C TRIBOLLET E DREIFUSS JJ SAWYER WH WO NC CHAN WY KOLODZIEJCZYK AS CHENG LL MANNING M

Citation: Y. Ala et al., PROPERTIES OF A NEW RADIOIODINATED ANTAGONIST FOR HUMAN VASOPRESSIN V-2 AND V-1A RECEPTORS, European journal of pharmacology, 331(2-3), 1997, pp. 285-293

Authors: MORIN D ALA Y DUMAS R

Citation: D. Morin et al., CONGENITAL NEPHROGENIC DIABETES-INSIPIDUS, Archives de pediatrie, 2(6), 1995, pp. 560-567

Authors: CHINI B MOUILLAC B ALA Y BALESTRE MN TRUMPPKALLMEYER S HOFLACK J ELANDS J HIBERT M MANNING M JARD S BARBERIS C

Citation: B. Chini et al., TYR115 IS THE KEY RESIDUE FOR DETERMINING AGONIST SELECTIVITY IN THE V1A VASOPRESSIN RECEPTOR, EMBO journal, 14(10), 1995, pp. 2176-2182

Authors: SERRADEILLEGAL C WAGNON J GARCIA C LACOUR C GUIRAUDOU P CHRISTOPHE B VILLANOVA G NISATO D MAFFRAND JP LEFUR G GUILLON G CANTAU B BARBERIS C TRUEBA M ALA Y JARD S

Citation: C. Serradeillegal et al., BIOCHEMICAL AND PHARMACOLOGICAL PROPERTIES OF SR-49059, A NEW, POTENT, NONPEPTIDE ANTAGONIST OF RAT AND HUMAN VASOPRESSIN V1A RECEPTORS, The Journal of clinical investigation, 92(1), 1993, pp. 224-231